JCR Pharmaceuticals Consolidates Cybersecurity on CrowdStrike Falcon to Enhance Sensitive Data Protection

CrowdStrike Japan K.K., the Japanese subsidiary of CrowdStrike (NASDAQ:CRWD), announced today that JCR Pharmaceuticals Co., Ltd. has deployed the AI-native CrowdStrike Falcon® platform to strengthen its security foundation across R&D, manufacturing, and sales. By consolidating cybersecurity across endpoints, identity, and data onto the Falcon platform, JCR Pharmaceuticals has visualized exposure risks for highly sensitive patient information and clinical trial data, accelerating threat detection and response.

Founded in 1975, JCR Pharmaceuticals is an R&D-driven pharmaceutical company specializing in rare diseases, known for its unique 'J-Brain Cargo®' technology that crosses the blood-brain barrier. Protecting research outcomes and patient data is a top priority for the company, alongside ensuring the stable operation of ICT systems that support medicine supply. Before the deployment, the burden of managing multiple individual security tools was a major challenge. Consolidation on the Falcon platform has enabled correlation analysis of logs and cross-domain visibility, shifting operations from reactive to proactive, data-driven decision-making.

Currently, the company utilizes 10 CrowdStrike Falcon modules, including Falcon Prevent, Insight XDR, Next-Gen SIEM, Data Security, Falcon Complete, and Adversary OverWatch. This setup balances reduced workload for the security team with advanced risk management. Michio Nishida, Manager of the Information Systems Department at JCR Pharmaceuticals, stated that the integration has made it easier to grasp the overall situation, making daily responses more practical and sustainable.